---
title: "Charles River Laboratories International, Inc. (CRL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CRL.US.md"
symbol: "CRL.US"
name: "Charles River Laboratories International, Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-20T06:50:21.095Z"
locales:
  - [en](https://longbridge.com/en/quote/CRL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CRL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CRL.US.md)
---

# Charles River Laboratories International, Inc. (CRL.US)

## Company Overview

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.criver.com](https://www.criver.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.64)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 42 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.11% |  |
| Net Profit YoY | -485.02% |  |
| P/B Ratio | 2.46 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7221787758.90 |  |
| Revenue | 4027044000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -6.02% | D |
| Profit Margin | -4.59% | D |
| Gross Margin | 32.44% | C |
| Revenue YoY | 0.11% | C |
| Net Profit YoY | -485.02% | E |
| Total Assets YoY | 1.95% | C |
| Net Assets YoY | -7.82% | D |
| Cash Flow Margin | -328.74% | E |
| OCF YoY | 0.11% | C |
| Turnover | 0.53 | C |
| Gearing Ratio | 61.34% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Charles River Laboratories International, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.11%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-485.02%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.46",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7221787758.90",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4027044000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-6.02%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-4.59%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "32.44%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "0.11%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-485.02%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.95%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "-7.82%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-328.74%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "0.11%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.53",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "61.34%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -39.76 | 54/59 | - | - | - |
| PB | 2.50 | 27/59 | 2.80 | 2.55 | 2.32 |
| PS (TTM) | 1.82 | 15/59 | 2.27 | 2.05 | 1.88 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 10 | 59% |
| Overweight | 2 | 12% |
| Hold | 5 | 29% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 152.43 |
| Highest Target | 265.00 |
| Lowest Target | 135.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CRL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CRL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CRL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CRL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**